Multiple law firms filed a securities fraud class-action lawsuit against GRAIL, Inc. and its executives. The legal action alleges the company made misleading statements regarding its NHS-Galleri cancer trial.
GRAIL shares plummeted more than 50% on February 20, 2026. This sell-off occurred after the company revealed the trial failed to meet its primary endpoint. The study did not achieve a statistically significant reduction in late-stage cancer diagnoses.
The lawsuit represents investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026. Affected shareholders have until August 4, 2026, to petition the court for lead plaintiff status.